CAMP — Camp4 Therapeutics Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1736730 ·
Last close
$4.00
Market Cap
$251.02M
52W High
$7.75
52W Low
$2.90
ADV30
138,616
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,899,000 — -14,029,000 -28,956,000 134,013,000 124,522,000 26,919,000
Jun 2026 1,779,000 — -13,380,000 -33,530,000 93,428,000 86,398,000 94,121,000
Mar 2026 1,294,000 — -13,071,000 -18,331,000 105,457,000 99,209,000 74,555,000
Dec 2025 348,000 — -12,776,000 -40,284,000 117,808,000 109,517,000 70,104,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-28,591,000
Investing CF
$-93,000
Financing CF
$76,030,000
CapEx
$-279,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.07
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-344,017,000
Inventory
—
Receivables
$217,000
ST Investments
—
EBIT TTM
$-52,384,000
Pretax Income TTM
$-107,244,000
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,320,000
EBITDA
$-50,832,000
Free Cash Flow
$-14,889,250
Enterprise Value
$136,710,048
Total Cash
$124,522,000
Total Debt
$6,450,000
Shares Out
62,754,200
Trailing EPS
$-2.11
Book Value
$1.71
ROE
-146.1%
ROA
-29.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,498,000 -52,061,000 -80,403,000 117,808,000 70,104,000 47,704,000 -29,553,000
Dec 2024 652,000 -53,088,000 -51,791,000 78,307,000 15,163,000 63,144,000 -45,562,000
Dec 2023 350,000 -51,879,000 -49,291,000 54,946,000 178,676,000 -123,730,000 -44,155,000
Dec 2022 0 -45,001,000 -44,192,000 102,549,000 180,080,000 -77,531,000 -38,543,000

TTM Snapshot

Revenues TTM
$4,216,000
NetIncome TTM
$-107,244,000
OpCashFlow TTM
—
Assets (Latest)
$93,428,000
Forward EPS
$-0.85

Peers — same industry

TickerNameMarket CapLastDaily %
NWBO NORTHWEST BIOTHERAPEUTICS INC $250.73M $0.15 —
ENTA ENANTA PHARMACEUTICALS INC $253.10M $8.69 —
PRE Prenetics Global Ltd $248.19M $16.33 —
QTTB Q32 Bio Inc. $258.24M $8.63 —
LFCR LIFECORE BIOMEDICAL, INC. \DE\ $242.22M $6.39 —

News headlines (Yahoo Finance, 1h cache)

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-17 21:05 · Yahoo
CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data
2026-11-11 09:12 · Yahoo
CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears
2026-11-10 02:14 · Yahoo
CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates
2026-11-06 00:00 · Yahoo
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
2026-11-05 21:05 · Yahoo
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2026-10-29 13:00 · Yahoo
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
2026-10-27 12:00 · Yahoo
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
2026-10-20 15:04 · Yahoo
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
2026-10-14 12:00 · Yahoo
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
2026-09-28 19:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.